CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.
Saved in:
| Title: | CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy. |
|---|---|
| Authors: | Su X; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA., Kobayashi T; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.; Department of Breast Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Xiang J; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Xu Y; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Shajahan-Haq AN; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA., Mardani M; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Noordeen S; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., O'Donnell K; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Kwakwa KA; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Guan D; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Fox GC; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Fontana F; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Cybulla E; Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210, USA., Bakewell S; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Vindigni A; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA., Veis DJ; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.; Musculoskeletal Research Center, Histology and Morphometry Core, Washington University School of Medicine, St. Louis, MO 63110, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA., Achilefu S; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX 7530, USA., Lanza GM; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA., Weilbaecher KN; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.; Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA. |
| Source: | Journal of bone oncology [J Bone Oncol] 2026 Apr 25; Vol. 58, pp. 100765. Date of Electronic Publication: 2026 Apr 25 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101610292 Publication Model: eCollection Cited Medium: Print ISSN: 2212-1366 (Print) Linking ISSN: 22121366 NLM ISO Abbreviation: J Bone Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
